drugset / Trial / NCT04194528

S1916 Digital Medicine Program for Pain Control in Cancer Patients

NCT04194528

NaSingle-groupOpen-labelSupportive care

Summary

This is a feasibility study to assess the use of a Digital Medicine Program (consisting of an FDA-approved ingestible sensor co-encapsulated with oxycodone/acetaminophen (5 mg/325 mg), a small wearable patch, and a mobile application) in cancer patients with metastatic disease experiencing uncontrolled pain.

Timeline

Start
2020-01-22
Primary completion
2020-09-16
Completion
2020-09-16

Drugs

EvaluationDrugModalityDoseRoute
Background Acetaminophen Small molecule 325 mg
Background Oxycodone Other / unclassified 5 mg